Papers - FUJIHARA Kazuo
-
Time-Dependent Analysis of Sicca Symptoms and Anti-Ro/SSA and Anti-La/SSB Antibodies in Patients with AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Akaishi T, Takahashi T, Misu T, Fujihara K, Nakashima I, Aoki M.
Tohoku J Exp Med. 260 ( 3 ) 215 - 221 2023.7
-
Pathology of MOGAD: a comparison with MS and AQP4 antibody-positive NMOSD.
Takai Y, Misu T, Fujihara K, Aoki M.
Front Neurol. 21 ( 14 ) 1209749 2023.7
-
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Motalban X, Shi FD, Tintore M, Xue Q, Yang C, Zhou H.
Ther Adv Neurol Disord. 14 ( 16 ) 2023.7
-
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.
Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K.
Ther Adv Neurol Disord. 16 2023.6
-
Attack adjudication in neuromyelitis optica spectrum disorder: substantiation of criteria by magnetic resonance imaging and biomarkers in N-Momentum.
Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigator.
Mult Scler. 29 ( 8 ) 945 - 955 2023.6
-
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Seze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto MA, Law L, Leite IS, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A.
Neurol Neuroimmunol Neuroinflamm. 10 ( 4 ) e200124 - e200124 2023.5
-
White blood cell count profiles in the acute phase of AQP4-IgG seropositive NMOSD and MOG-IgG-associated disease.
Akaishi T, Misu T, Fujihara K, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Kaneko K, Takahashi T, Fujimori J, Takai Y, Nishiyama S, Ishii T, Aoki M, Nakashima I, Hozawa A.
Sci Rep. 13 ( 1 ) 6481 - 6481 2023.4
-
Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): International MOGAD Panel Proposed Criteria.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan E, Ramanathan S, Waters P, Tenembaum S, MD, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock S, Fujihara K, Palace J.
Lancet Neurol. 22 ( 3 ) 268 - 282 2023.3
-
Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images.
Tomura N, Saginoya T, Sanpei T, Konno T, Fujihara K.
Acta Radiol 64 ( 2 ) 719 - 724 2023.2
-
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
Bennett JL, Fujihara K, Kim HJ, Marignier R, O’Connor KC, Sergott RC, Traboulsee A, Wiendl H, Wuerfel J, Zamvil SS, Anania VG, Buffels R, Künzel T, Lekkerkerker AN, Lennon-Chrimes S, Pittock SJ.
Front Neurol. 17 ( 14 ) 1114667 2023.2
-
A novel association of osmotic demyelination in Sjogren’s syndrome ¨ prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review.
Sandhya P, Akaishi T, Fujihara K, Aoki M.
Mult Scler Relat Disord. 69 104466 2023.1
-
Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, von Büdingen HC, Klingelschmitt G, Stokmaier D, Bennett JL.
Neurol Neuroimmunol Neuroinflamm. 10 ( 1 ) e200071 2022.12
-
Diagnosis and classification of optic neuritis.
Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov M, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi P, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, DeSeze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Froment Tilikete C, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Hernández Martínez de Lapiscina E, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales A, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, Van Pesch V, Wang AG, Wattjes M, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT.
Lancet Neurol. 21 ( 12 ) 1120 - 1134 2022.12
-
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC on behalf of the N-MOmentum study investigators.
EBioMedicine. 86 104321 2022.12
-
Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Kissani N, Ouadika1 RJB, Kishk NA, Chaymae O, Ibrahim EAA, Maiga Y, Paul R, Daniel GM, Hamid A, Assogba K, Gaye NM, Hor JY, Tegueu CK, Marignier R, Palace J, Weinshenker BG, Ragab AH, Fujiharaa K. Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Open Access Library J. e9649 2022.9
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 269 ( 6 ) 3136 - 3146 2022.6
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022.5
-
Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series.
Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC, Hemingway C, Matsushima J, Sugaya N, Yamashita M, von Büdingen HC, Miyamoto K.
Mult Scler Relat Disord. 61 103772 2022.5
-
RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO.
4. Iwamoto S, Itokazu T, Sasaki A, Kataoka H, Tanaka S, Hirata T, Miwa K, Suenaga T, Takai Y, Misu T, Fujihara K, Yamashita T.
Ann Neurol. 91 ( 4 ) 532 - 547 2022.4
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022.3